********** downramps Resapp, page-295

See, I don’t agree. Firstly, ‘last time’ has no bearing on ‘next time’, since it was driven by irrational exuberance rather than fundamentals (let’s face it, there hasn’t been a genuine fundamental at play in this whole sorry saga). And that exuberace has been tempered by the most recent results, so while you’ll certainly get a spike, it’s very unlikely to be as big.

And the 60c+ on FDA approval values this thing at, dunno, half a billion? More? That figure is about as far removed from reality as Jim Carey.

I admire your passion, but I have to say, I’m concerned you’re not thinking straight about RAP and it could end up costing you dearly. To me, this whole thing is a gimmick designed to seperate shareholders from their money. But as with most things, the truth probably lies somewhere between my point of view and yours.